CFO
LGND icon

CVA Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

CVA Family Office’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85K Buy
9
+3
+50% +$707 ﹤0.01% 1445
2026
Q1 		$1.2K Buy
+6
New +$1.19K ﹤0.01% 1624

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's LGND Position: Q2 2026 in Review

CVA Family Office increased its Ligand Pharmaceuticals (LGND) stake by 50% in Q2 2026, buying an estimated $707 and bringing the position to 9 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

CVA Family Office first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • CVA Family Office held 9 shares of Ligand Pharmaceuticals worth $2.85K as of Q2 2026.
  • CVA Family Office bought 3 Ligand Pharmaceuticals shares in Q2 2026, an estimated $707.
  • Ligand Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1445 holding.
  • CVA Family Office first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.